Biospeciation of Potential Vanadium Drugs of Acetylacetonate in the Presence of Proteins
Sciortino, Giuseppe (Universitat Autònoma de Barcelona. Departament de Química)
Ugone, Valeria (Università di Sassari. Dipartimento di Chimica e Farmacia)
Sanna, Daniele (Consiglio Nazionale delle Ricerche. Istituto di Chimica Biomolecolare)
Lubinu, Giuseppe (Università di Sassari. Dipartimento di Chimica e Farmacia)
Ruggiu, Simone (Università di Sassari. Dipartimento di Chimica e Farmacia)
Maréchal, Jean-Didier (Universitat Autònoma de Barcelona. Departament de Química)
Garribba, Eugenio (Università di Sassari. Dipartimento di Chimica e Farmacia)

Fecha:	2020
Resumen:	Among vanadium compounds with potential medicinal applications, [V IV O(acac)] is one of the most promising for its antidiabetic and anticancer activity. In the organism, however, interconversion of the oxidation state to +III and +V and binding to proteins are possible. In this report, the transformation of V III (acac), V IV O(acac), and V V O(acac) after the interaction with two model proteins, lysozyme (Lyz) and ubiquitin (Ub), was studied with ESI-MS (ElectroSpray Ionization-Mass Spectroscopy), EPR (Electron Paramagnetic Resonance), and computational (docking) techniques. It was shown that, in the metal concentration range close to that found in the organism (15-250 μM), V III (acac) is oxidized to V IV O(acac) + and V IV O(acac), which-in their turn-interact with proteins to give n [V IV O(acac)]-Protein and n [V IV O(acac)]-Protein adducts. Similarly, the complex in the +IV oxidation state, V IV O(acac), dissociates to the mono-chelated species V IV O(acac) + which binds to Lyz and Ub. Finally, V V O(acac) undergoes complete dissociation to give the 'bare' V V O ion that forms adducts n [V V O]-Protein with n = 1-3. Docking calculations allowed the prediction of the residues involved in the metal binding. The results suggest that only the V IV O complex of acetylacetonate survives in the presence of proteins and that its adducts could be the species responsible of the observed pharmacological activity, suggesting that in these systems V IV O 2+ ion should be used in the design of potential vanadium drugs. If V III or V V O potential active complexes had to be designed, the features of the organic ligand must be adequately modulated to obtain species with high redox and thermodynamic stability to prevent oxidation and dissociation.
Ayudas:	Ministerio de Economía, Industria y Competitividad CTQ2017-87889-P Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1323
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Metal drugs ; Vanadium ; Anticancer action ; Antidiabetic action ; Proteins ; Transport in the organism ; Drug design
Publicado en:	Frontiers in chemistry, Vol. 8 (May 2020) , art. 345, ISSN 2296-2646

DOI: 10.3389/fchem.2020.00345
PMID: 32457872

11 p, 1.7 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados